Vatinoxan – a new development for the clinical use of α2-adrenoceptor agonists in dogs: part 2

2021 ◽  
Vol 26 (10) ◽  
pp. 1-4
Author(s):  
Rachel C Bennett

The first article in this two part series explored the pharmacodynamics of vatinoxan as a peripherally acting α2 adrenoceptor agonist, and in this installment the pharmacokinetics of vatinoxan and its effect on coadministered drugs are explored.

1985 ◽  
Vol 68 (s10) ◽  
pp. 129s-132s ◽  
Author(s):  
C. R. Jones ◽  
C. A. Hamilton ◽  
K. F. Whyte ◽  
H. L. Elliott ◽  
J. L. Reid

1. Agonist regulation of platelet α2-adrenoceptors was examined in human volunteers after acute elevations of adrenoceptor agonist and during chronic elevation of plasma catecholamines in two patients with phaeochromocytoma. 2. Platelet α2-adrenoceptor number was measured by radioligand binding ([3H]yohimbine) and α2-adrenoceptor function measured by turbidimetric platelet aggregation. 3. Short term infusion of adrenoceptor agonists with α2 activity caused reductions in the platelet response to adrenaline in vitro; conversely an increase in activity was observed postoperatively in two patients after removal of phaeochromocytoma. 4. The changes in platelet response were not accompanied by changes in α2-adrenoceptor number. 5. It is proposed that a process of receptor inactivation occurs during desensitization and this is responsible for the dynamic regulation of platelet responses.


2020 ◽  
Author(s):  
Akash . ◽  
M. Hoque ◽  
Amarpal .

Most commonly used α2-adrenoceptor agonist shows adverse cardiovascular effects during anaesthesia. They mainly depress the cardiovascular system by provoking vasoconstriction followed by bradycardia. Although α2-adrenoceptor antagonist like atipamezole can reverse these effects along with that they also reverse the sedation and nociception. Concomitant administration of peripherally acting α2-adrenoceptor antagonist MK-467 can reverse the adverse cardiovascular effect of α2-adrenoceptor agonists without affecting the sedation and nociception. MK-467 has been successfully used in different animals like dogs, cats, sheep, horses along with different α2-adrenoceptor agonist drugs. This review aims to summarize the effects of MK-467 on sedation, cardiopulmonary system, the minimum alveolar concentration of different inhalant anaesthetics, plasma drug concentration, plasma glucose and insulin in different animals.


2018 ◽  
Vol 105 (3) ◽  
pp. 225-232
Author(s):  
DR Monks ◽  
SJ Bund

Purpose This study was performed to investigate the influence of α-adrenoceptor subtypes upon ureteral smooth muscle contractile responses. Methods Rat ureters were challenged in vitro with noradrenaline (NA), the α1-adrenoceptor agonist phenylephrine (PE), and the α2-adrenoceptor agonist clonidine (CLON). The influences of the agonists on the magnitude and frequency of acetylcholine (ACh)-stimulated phasic contractile responses were recorded. Results The magnitude of the phasic contractile responses effected by ACh was not significantly influenced by the adrenoceptor agonists, but the frequency of the response was significantly enhanced by all three agonists (p < 0.05). Idazoxan and prazosin abolished the rise in frequency effected by CLON and PE, respectively, whereas both antagonists in combination were required to abolish the increase in frequency effected by NA. Conclusions It has been demonstrated that α1- and α2-adrenoceptors modulate the contractile function of rat ureteral smooth muscle by increasing the frequency, but not the magnitude, of phasic contractile responses. The enhancement of contractile function by NA is mediated by mechanisms dependent upon both α1- and α2-adrenoceptors.


1986 ◽  
Vol 70 (2) ◽  
pp. 147-153 ◽  
Author(s):  
C. R. Jones ◽  
M. Giembcyz ◽  
C. A. Hamilton ◽  
I. W. Rodger ◽  
K. Whyte ◽  
...  

1. The effect of intravenous infusion of catecholamines and related drugs on human platelet α2-adrenoceptor number and function was investgated. 2. Short (60–120 min) infusions of catecholamines with α2 agonist activity in vivo produced attenuation of the platelet responses to adrenaline in vitro. This desensitization was specific for the adrenaline induced aggregatory response. 3. The maximum number of [3H]yohimbine binding sites on platelets was not altered by adrenaline infusion. 4. The ability of adrenaline to reduce platelet cyclic AMP levels was significantly reduced after the infusions. 5. Acute infusions of α2-adrenoceptor agonists may alter the coupling of the platelet α2-adrenoceptor to adenylate cyclase.


1997 ◽  
Vol 35 (6) ◽  
pp. 561-568
Author(s):  
GYÖNGI HORVÁTH ◽  
ILDIKÓ DOBOS ◽  
PÉTER LISZLI ◽  
WALTER KLIMSCHA ◽  
MARGIT SZIKSZAY ◽  
...  

2001 ◽  
Vol 105 (2) ◽  
pp. 159-166 ◽  
Author(s):  
David B Bylund ◽  
Moira E Gerety ◽  
H.Kevin Happe ◽  
L.Charles Murrin

1985 ◽  
Vol 108 (2) ◽  
pp. 184-191 ◽  
Author(s):  
Bo Ahrén

Abstract. The effects of various α-adrenoceptor agonists and antagonists on blood radioiodine levels were studied in mice pre-treated with 125I and thyroxine. The non-selective α-adrenoceptor agonist noradrenaline and the selective α1-adrenoceptor agonist phenylephrine both enhanced blood radioiodine levels. Noradrenaline was more potent than phenylephrine. Contrary, the selective α2-adrenoceptor agonist clonidine depressed basal levels of blood radioiodine. The non-selective α-adrenoceptor antagonist phentolamine and the selective α1-adrenoceptor antagonist prazosin both inhibited the noradrenaline-induced elevation of radioiodine levels, whereas the α2-adrenoceptor antagonist yohimbine had no such effect, except at a high dose level. All three α-adrenoceptor agonists, noradrenaline, phenylephrine and clonidine, inhibited the radioiodine response to TSH. In addition, TSH-induced increase in radioiodine levels was inhibited by prazosin, whereas yohimbine had no effect. Phentolamine inhibited the radioiodine response to TSH when given 2 h prior to TSH, whereas when given 15 min prior to TSH the response to TSH was potentiated by Phentolamine. It is concluded, that under in vivo conditions in the mouse, α1-adrenoceptor activation stimulates basal thyroid hormone secretion and inhibits TSH-induced thyroid hormone secretion. Further, α2-adrenoceptor activation inhibits basal thyroid hormone secretion. In addition, TSH-induced thyroid hormone secretion is inhibited by α1-adrenoceptor antagonism. Thus, α-adrenoceptors induce both stimulatory and inhibitory effects of thyroid function.


Sign in / Sign up

Export Citation Format

Share Document